Skip to main content

Table 4 Participant timeline

From: Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial

  1. *Need for subsequent tolvaptan doses on days 2 and 3 reassessed daily according to protocol (based on serum sodium increment)
  2. **Usual care may include fluid restriction or tolvaptan (patients administered tolvaptan prior to enrolment will not be included)
Back to article page

Trials

ISSN: 1745-6215